- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03154320
A Trial of Same-Day Testing and Treatment to Improve Outcomes Among Symptomatic Patients Newly Diagnosed With HIV
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study is a randomized trial that will compare outcomes with standard and same-day treatment among patients with TB symptoms at HIV diagnosis. The standard group will receive same-day chest x-ray as well as Xpert Ultra testing with a spot specimen (with 48-hour turn-around-time). Participants will return for Xpert Ultra results and early morning sputum testing on Day 2. TB treatment will be provided on the day of diagnosis (Day 0 for those with high clinical and radiographic suspicion of TB, and Day 2 for those diagnosed by spot Xpert Ultra). Standard group participants who are not diagnosed with TB will be tested and treated for other opportunistic infections (OIs), as clinically indicated, and will initiate ART on Day 7. The same-day group will receive Xpert Ultra testing (with same-day results) and chest x-ray with same-day ART or TB treatment (on Day 0) based on test results. They will also be tested and treated for other OIs as clinically indicated. They will provide early morning sputum for repeat testing on Day 1. Both groups will receive Xpert Ultra testing on both spot and early morning specimens, with liquid culture on both specimens as the diagnostic gold standard; those with TB will start ART according to WHO guidelines.
Three specific aims are proposed:
Aim 1: To compare the proportion of participants in each group who are alive and in care with undetectable viral load (<200 copies/ml) at 48 weeks after HIV testing. Hypothesis: The proportion of participants retained in care with undetectable viral load will be 51% in the standard and 65% in the same-day group.
Aim 2: To compare mortality in each group at 48 weeks after HIV testing. Hypothesis: Mortality will be 10% in the standard group and 4% in the same-day group.
Aim 3: To conduct a comparison of cost and cost-effectiveness of standard and same-day care, where cost is measured by the mean treatment cost and effectiveness is measured by being alive and in care with plasma HIV-1 RNA level <200 copies/ml at 48 weeks after HIV testing. Hypothesis: Same-day treatment will cost less per patient retained in care with undetectable viral load.
Aim 4: To determine the rates of ART and TB treatment initiation, TB diagnosis after ART initiation, IRIS, adverse events, and adherence in both groups, and to evaluate the sensitivity, specificity, and predictive values of single tests and different testing combinations compared to liquid mycobacterial culture results.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Port-au-Prince, Haïti
- GHESKIO
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Men and women of ≥18 years of age
- Presence of cough, fever, night sweats or weight loss
- Ability and willingness to give written informed consent
- Documentation of positive HIV status (test conducted at GHESKIO)
- Acceptance of HIV diagnosis, defined as affirmative responses to two questions: "I believe that HIV and AIDS exist" and "I believe that the results of my HIV test show that I am infected".
Exclusion Criteria:
- Any use of ART in the past
- Treatment for TB in the year prior to screening visit
- Pregnancy or breastfeeding at the screening visit
- Active drug, alcohol use, or mental condition that would interfere with the ability to adhere to study requirements, in the opinion of the study physician
- Score of <3 for any of the 7 questions on the ART readiness survey
- Planning to transfer care to another clinic during the study period
- Symptoms consistent with WHO stage 4 neurologic disease (cryptococcal meningitis, TB meningitis; central nervous system toxoplasmosis; HIV encephalopathy; progressive multifocal leukoencephalopathy)
- Severe illness, classified as one of the WHO "danger signs" of temperature >39 degrees Celsius, pulse >120 beats/minutes, respiratory rate >30, or inability to walk unaided.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: Standard Group
On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results).
Those with high clinical/radiographic suspicion for TB will start same-day TB treatment.
On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing.
Those who are Xpert Ultra positive will start TB treatment.
Those who are not diagnosed with TB will start ART on Day 7, after testing and treatment for other opportunistic infections.
A liquid TB culture will be performed on both the spot and early morning specimens.
|
Traitement standard
|
Expérimental: Same-Day Treatment Group
On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results.
Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis.
Those who are diagnosed with TB will start same-day TB treatment.
Those who are not diagnosed with TB will start same-day ART.
|
Treatment with ART or TB medication on day of HIV diagnosis
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Retention in care with viral suppression
Délai: 48 weeks after HIV testing
|
Proportion of participants who are in care with HIV-1 RNA <200 copies/ml
|
48 weeks after HIV testing
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Mortality
Délai: 48 weeks after HIV testing
|
All-cause mortality
|
48 weeks after HIV testing
|
Mean treatment cost per participant
Délai: 48 weeks after HIV testing
|
Mean treatment cost per participant
|
48 weeks after HIV testing
|
Viral suppression
Délai: 48 weeks after HIV testing
|
Proportion of participants with HIV-1 RNA <50 copies/ml and <1000 copies/ml
|
48 weeks after HIV testing
|
Adherence by medication possession ratio
Délai: 48 weeks after HIV testing
|
Proportion of participants with 48-week adherence to ART of at least 90% by pharmacy refill records
|
48 weeks after HIV testing
|
Adherence by 3-day self-report
Délai: 48 weeks after HIV testing
|
Proportion of participants with perfect (100%) adherence as measured by 3-day self-report at 48 weeks after HIV testing
|
48 weeks after HIV testing
|
Treatment failure
Délai: 48 weeks
|
Proportion of participants meeting WHO criteria for ART failure and proportion initiating second-line ART during the study period
|
48 weeks
|
TB testing characteristics
Délai: These diagnostic tests will be conducted during the first week of study enrollment
|
Sensitivity, specificity, predictive values, and likelihood ratios of spot and early morning Xpert Ultra results and chest x-ray, as single and as combined tests, with liquid culture as gold standard
|
These diagnostic tests will be conducted during the first week of study enrollment
|
Time in clinic
Délai: First study day and first study month
|
Median time spent in clinic during first day and month of the study
|
First study day and first study month
|
Coping with HIV diagnosis
Délai: 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the COPE survey
|
2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Connectedness to Treatment Setting
Délai: 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the Connectedness to Treatment Setting Scale
|
2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
TB diagnosis after ART initiation
Délai: 48-week study period
|
Diagnosis of culture-positive TB after ART initiation (BACTEC MGIT 960, Becton Dickinson)
|
48-week study period
|
Incidence of immune reconstitution inflammatory syndrome (IRIS)
Délai: 48-week study period
|
Incidence of paradoxical or unmasking IRIS
|
48-week study period
|
Adverse events
Délai: 48-week study period
|
New Division of AIDS Grade 3 or Grade 4 signs, symptoms, or laboratory abnormalities that are at least a one-grade increase from baseline
|
48-week study period
|
Measure of hope and optimism
Délai: 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the State Hope Scale
|
2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Patient satisfaction
Délai: 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the HRSA Patient Satisfaction Survey
|
12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Time to death
Délai: 48-week study period
|
Days to death
|
48-week study period
|
Last missed dose of medication
Délai: 2 Weeks, 12 Weeks, 24 Weeks, 48 Weeks
|
Proportion of participants who report last missed dose of ART was at least 2 weeks ago
|
2 Weeks, 12 Weeks, 24 Weeks, 48 Weeks
|
Collaborateurs et enquêteurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AI131998
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur VIH/SIDA
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
-
Atara BiotherapeuticsRecrutementTroubles lymphoprolifératifs | Léiomyosarcome | Complications de la greffe de cellules souches | Complications de greffe d'organe solide | Maladies associées au virus Epstein-Barr (EBV) | EBV+ Maladie lymphoproliférative post-transplantation (EBV+ PTLD) | Greffe allogénique de cellules hématopoïétiques et d'autres conditionsÉtats-Unis, L'Autriche, Belgique, France, Italie, Espagne, Royaume-Uni
-
Atara BiotherapeuticsPlus disponibleTroubles lymphoprolifératifs | Complications de la greffe de cellules souches | Infections par le virus Epstein-Barr (EBV) | Lymphome associé à EBV+ | Maladie lymphoproliférative post-transplantation associée à EBV+ (EBV+ PTLD) | Virémie d'Epstein-Barr | Lymphome lié au SIDA | Maladie lymphoproliférative... et d'autres conditions
Essais cliniques sur Traitement standard
-
Hospital Clinic of BarcelonaInconnue
-
Columbia UniversityNeurolutions, Inc.RetiréAccident vasculaire cérébral | Hémiparésie
-
University of MichiganWallace H Coulter Center for Translational ResearchComplété
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI)Complété
-
Memorial Sloan Kettering Cancer CenterRésiliéLes familles ou proches parents des patients traités au MSKCC pour des carcinomes épidermoïdes non cutanés du | Voies aérodigestives supérieuresÉtats-Unis
-
University of PaviaActif, ne recrute pasReflux gastro-oesophagien | Érosion dentaireItalie
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); The Emmes Company, LLC; National Drug...ComplétéSurdose d'opioïdesÉtats-Unis
-
University of OklahomaComplétéGain de poids | Trouble de l'alimentation Néonatal | Nourrisson de très faible poids à la naissanceÉtats-Unis
-
University of GlasgowComplétéLa maladie de Crohn | Modification alimentaireRoyaume-Uni
-
Galderma R&DComplétéLes rides | Plis Nasolabiaux | Lignes de marionnettes